Medical management of recurrent aggressive angiomyxoma with gonadotropin-releasing hormone agonist.
Patients with aggressive angiomyxoma may experience local recurrences. We report a case of recurrent aggressive angiomyxoma medically treated successfully with a gonadotropin-releasing hormone agonist. A 34-year-old woman with a huge perineal tumor underwent an extensive resection of the abdominoperineal tumor combined with total pelvic exenteration. Histology showed aggressive angiomyxoma and the tumor cells were immunoreactive for estrogen and progesterone receptors. Although the patient had experienced no local recurrence for 12 months under adjuvant therapy with a gonadotropin-releasing hormone agonist, a recurrence occurred 3 months after the completion of adjuvant therapy. The patient underwent medical treatment with a gonadotropin-releasing hormone agonist and had a complete resolution of the recurrent tumor again. Hormonal treatment with a gonadotropin-releasing hormone agonist can be applied for small primary aggressive angiomyxomas in addition to adjuvant therapy for residual tumors.
Shinohara
Nobuo
N
Department of Urology, Graduate School of Medicine, Hokkaido University, Kitaku, Sapporo, Japan. nobuo-s@med.hokudai.ac.jp
Nonomura
Katsuya
K
Ishikawa
Shuhei
S
Seki
Haruo
H
Koyanagi
Tomohiko
T
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D009232:Myxoma / Q000473:pathology / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D010386:Pelvic Neoplasms / Q000473:pathology / Q000628:therapy*; D010502:Perineum; D014547:Urinary Diversion
D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide